azacitidine has been researched along with fazarabine in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (45.65) | 18.7374 |
| 1990's | 24 (52.17) | 18.2507 |
| 2000's | 1 (2.17) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, MM; Beisler, JA; Driscoll, JS | 1 |
| Abbruzzese, JL; Frost, P | 1 |
| Abbruzzese, JL; Ajani, JA; Daugherty, K; Hubbard, KP; Levin, B; Pazdur, R | 1 |
| Esparza, L; Holmes, FA; Hortobagyi, GN; Theriault, RL; Walters, RS | 1 |
| Amato, R; Ho, D; Krakoff, IH; Raber, M; Schmidt, S | 1 |
| Casper, ES; Kelsen, DP; Schwartz, GK | 1 |
| McCulloch, EA; Yang, GS | 1 |
| Ben-Baruch, N; Cowan, KH; Fine, R; Ford, H; Kelley, JA; Surbone, A; Thomas, RV | 1 |
| Allegra, CJ; Grem, JL | 2 |
| Alberti, D; Arzoomanian, RZ; Bailey, H; Bruggink, J; Tombes, MB; Tutsch, KD; Wilding, G | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Hynes, HE; Keppen, M; Kuebler, JP; Metch, B; Schuller, DE | 1 |
| Cheng, YC; Cooney, D; Dutschman, G; Leclerc, JM; Townsend, A | 1 |
| Breitman, TR; Cooney, DA; Dalal, M; del Campo, AA; Driscoll, JS; Johns, DG; Plowman, J; Schuller, HM; Vistica, DT | 1 |
| Veselý, J | 1 |
| Covey, JM; Zaharko, DS | 1 |
| Driscoll, JS; Johns, DG; Plowman, J | 1 |
| Pískala, A; Veselý, J | 1 |
| Cihák, A; Skoda, J; Vesely, J | 1 |
| Ahluwalia, GS; Arnold, ST; Balzarini, J; Cohen, MB; Cooney, DA; Dalal, M; Johns, DG; Kang, GJ; McMahon, JB; Wilson, YA | 1 |
| Bhalla, K; Gleyzer, M; Grant, S | 1 |
| Antonsson, BE; Avramis, VI; Holcenberg, JS; Nyce, J | 1 |
| Cheng, YC; Townsend, AJ | 1 |
| Arlin, Z; Baker, M; Bhalla, K; Cole, J; Graham, G; Grant, S; MacLaughlin, W | 1 |
| Cradock, JC; Grem, JL; Grieshaber, CK; Harrison, SD; Hoth, DF; King, SA; Leyland-Jones, B; Plowman, J; Shoemaker, DD; Zaharko, D | 1 |
| Balis, FM; Heideman, RL; McCully, C; Poplack, DG | 1 |
| Balis, FM; Ettinger, LJ; Ford, H; Gillespie, A; Heideman, RL; Packer, RJ; Poplack, DG; Reaman, GH; Sato, J; Tan, C | 1 |
| Avramis, VI; Mecum, RA; Powell, WC | 1 |
| Durr, FE; Lindh, D; Wallace, RE | 1 |
| Asofsky, R; Hirschhorn, R; Kim, J; Ratech, H; Thorbecke, GJ | 1 |
| Glazer, RI; Knode, MC | 1 |
| Mojaverian, P; Repta, AJ | 1 |
| Crowley, JJ; Goodwin, JW; Livingston, RB; Panella, TJ; Williamson, SK | 1 |
| Novotný, L; Pískala, A; Vachálková, A | 1 |
| Bernstein, ML; Devine, S; Dubowy, R; Grier, H; Kung, F; Land, V; Murphy, S; Whitehead, VM | 1 |
| Eyre, HJ; Selby, GB; Townsend, J; Upchurch, C | 1 |
| Blessing, JA; Look, KY; Manetta, A | 1 |
| Avramis, VI; Kees, UR | 1 |
| Blessing, JA; Manetta, A; Mann, WJ; Smith, DM | 1 |
| Cowan, KH; Johnston, PG; Kleiner, D | 1 |
| Ben-Baruch, N; Cowan, KH; Denicoff, AM; Goldspiel, BR; O'Shaughnessy, JA | 1 |
| Ahluwalia, GS; Barchi, JJ; Cooney, DA; Covey, JM; Gharehbaghi, K; Hochman, I; Jayaram, HN; Paull, KD | 1 |
| Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Estey, E; Kantarjian, HM; Keating, MJ; O'Brien, S; Plunkett, W; Rios, MB; Sorenson, M; Wilhelm, M | 1 |
| Krynetskaia, NF; Krynetskiy, E; Mishra, AK; Phadke, MS | 1 |
4 review(s) available for azacitidine and fazarabine
| Article | Year |
|---|---|
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cells; Cytidine; Drug Resistance; Enzyme Activation; Eukaryotic Cells; Humans; Leukemia, Experimental; Liver Regeneration; Uridine Kinase | 1985 |
Azapyrimidine nucleosides: metabolism and inhibitory mechanisms.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azauridine; Decitabine; DNA; Gastric Mucosa; Leukemia, Experimental; Mice; Rats; RNA, Ribosomal | 1985 |
Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.
Topics: Antiviral Agents; Azacitidine; Humans | 1987 |
16 trial(s) available for azacitidine and fazarabine
| Article | Year |
|---|---|
Phase II trial of fazarabine in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Humans; Male; Middle Aged | 1992 |
Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Breast Neoplasms; Carcinoma; Drug Evaluation; Female; Humans; Middle Aged | 1992 |
Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1992 |
Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Azacitidine; Female; Humans; Infusion Pumps; Male; Middle Aged; Pancreatic Neoplasms | 1992 |
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1990 |
Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1991 |
Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged | 1991 |
Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study.
Topics: Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Drug Administration Schedule; Humans; Neoplasms | 1993 |
A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Azacitidine; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Southwestern United States; Treatment Failure | 1994 |
A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Female; Humans; Infusions, Intravenous; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome | 1995 |
A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Uterine Cervical Neoplasms | 1995 |
Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Azacitidine; Humans; Male; Neoplasms, Germ Cell and Embryonal | 1993 |
Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Azacitidine; Colonic Neoplasms; Drugs, Investigational; Female; Humans; Infusions, Intravenous; Male; Middle Aged | 1993 |
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia | 1997 |
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blast Crisis; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome | 1999 |
26 other study(ies) available for azacitidine and fazarabine
| Article | Year |
|---|---|
Synthesis and antitumor activity of 5-azacytosine arabinoside.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Leukemia L1210; Mice; Stereoisomerism | 1979 |
Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cisplatin; Decitabine; DNA, Neoplasm; Drug Resistance; Drug Synergism; Humans; Melanoma; Methylation; Mice; Sensitivity and Specificity; Tubercidin; Tumor Cells, Cultured | 1992 |
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |
Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Colorectal Neoplasms; Cytarabine; Cytidine Triphosphate; Deoxycytosine Nucleotides; DNA, Neoplasm; Humans; In Vitro Techniques; Tumor Cells, Cultured | 1990 |
Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Division; Cell Line; Cell Nucleus; Cell Survival; Colonic Neoplasms; Cytarabine; Cytidine; Deoxycytosine Nucleotides; DNA, Neoplasm; Drug Administration Schedule; Drug Interactions; Fluorouracil; Humans; Nucleic Acids; Thymine Nucleotides; Tumor Stem Cell Assay | 1991 |
Metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4).
Topics: Antineoplastic Agents; Azacitidine; Cells, Cultured; DCMP Deaminase; Deoxycytidine Kinase; DNA; Drug Stability; Humans; Kinetics; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Tritium | 1985 |
Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.
Topics: Animals; Azacitidine; Cell Cycle; Cell Differentiation; Cell Survival; Cells, Cultured; Humans; Mice; Microscopy, Electron; Neoplasm Transplantation; Neoplasms, Experimental; Vidarabine | 1986 |
Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cells, Cultured; Decitabine; Kinetics; Leukemia L1210; Male; Mice; Mice, Inbred Strains | 1985 |
Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Brain Neoplasms; Carmustine; Cytarabine; Leukemia L1210; Mice; Mice, Inbred Strains; Neoplasm Transplantation | 1985 |
Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Line; Cell Survival; Cytarabine; Decitabine; Drug Evaluation, Preclinical; Kinetics; Leukemia L1210; Leukocyte Count; Male; Mice; Mice, Inbred DBA; Nucleosides; Phosphorylation; Thymidine | 1986 |
Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
Topics: Animals; Azacitidine; Biological Transport; Colonic Neoplasms; Cytidine; Deoxycytidine; Deoxycytidine Kinase; DNA; Drug Resistance; Humans; Leukemia P388; Mice; Phosphorylation | 1986 |
Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
Topics: Azacitidine; Cell Division; Cell Line; Colony-Forming Units Assay; Cytarabine; Decitabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1986 |
Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.
Topics: Azacitidine; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Humans; Lymphoid Tissue; Methylation; Phosphotransferases | 1987 |
Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of chain elongation on a defined template.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Azacitidine; Base Sequence; Cell Line; DNA; DNA Polymerase I; DNA Polymerase II; Humans; Kinetics; Templates, Genetic | 1987 |
Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.
Topics: Acute Disease; Azacitidine; Bone Marrow; Decitabine; Deoxycytidine; Deoxycytosine Nucleotides; DNA, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia; Neoplastic Stem Cells | 1987 |
Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates.
Topics: Animals; Antineoplastic Agents; Azacitidine; Drug Evaluation, Preclinical; Half-Life; Macaca mulatta; Male; Mathematics | 1988 |
Phase I trial and pharmacokinetic evaluation of fazarabine in children.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms | 1989 |
Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Leukemia; Methylation; RNA, Neoplasm; Stereoisomerism; Time Factors; Tritium; Tumor Cells, Cultured | 1989 |
Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Stereoisomerism; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Topics: Adenosine Deaminase; Animals; Azacitidine; Body Weight; Coformycin; Deoxyadenosines; DNA; Lymphoma; Mice; Mice, Inbred AKR; Mice, Inbred BALB C; Neoplasm Transplantation; Nucleoside Deaminases; Organ Size; Pentostatin; Phenotype; Ribonucleosides; Spleen; T-Lymphocytes; Thymus Gland | 1984 |
1-beta-D-arabinosyl-5-azacytosine. Cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells.
Topics: Azacitidine; Cell Line; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Humans; Kinetics; Methylation; Stereoisomerism | 1984 |
Development of an intravenous formulation for the unstable investigational cytotoxic nucleosides 5-azacytosine arabinoside (NSC 281272) and 5-azacytidine (NSC 102816).
Topics: Antineoplastic Agents; Azacitidine; Benzoates; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Diethylhexyl Phthalate; Drug Incompatibility; Drug Stability; Injections, Intravenous; Plasticizers; Solubility | 1984 |
Polarographic reduction and carcinogenic index tg alpha of 5-aza nucleosides possessing antileukemic activity.
Topics: Antineoplastic Agents; Azacitidine; Carcinogens; Cytarabine; Cytidine; Molecular Structure; Oxidation-Reduction; Polarography; Structure-Activity Relationship | 1993 |
Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; DNA; Humans; Leukemia; Methylation; Tumor Cells, Cultured | 1995 |
Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Deoxycytidine; DNA, Neoplasm; Humans; Leukemia P388; Lymphocytes; Mice; Mice, Inbred Strains; Phosphorylation; Tumor Cells, Cultured | 1996 |
Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Lung Neoplasms | 2009 |